| 产品名称 | 产品编号 | CAS编号 | 分子式 = 分子量 | 位单 | 联系QQ |
| WP1066; WP1066 | CFN60218 | 857064-38-1 | C17H14BrN3O = 356.22 | 5mg | QQ客服：2159513211 |
| AZD7762; AZD7762 | CFN60219 | 860352-01-8 | C17H19FN4O2S = 362.42 | 5mg | QQ客服：2056216494 |
| Ralimetinib (LY2228820); Ralimetinib (LY2228820) | CFN60220 | 862507-23-1 | C24H29FN6.2CH4O3S = 612.74 | 5mg | QQ客服：2159513211 |
| Linsitinib (OSI-906); Linsitinib (OSI-906) | CFN60221 | 867160-71-2 | C26H23N5O = 421.49 | 5mg | QQ客服：2056216494 |
| 卡非佐米; Carfilzomib (PR-171) | CFN60222 | 868540-17-4 | C40H57N5O7 = 719.91 | 5mg | QQ客服：215959384 |
| PF-573228; PF-573228 | CFN60223 | 869288-64-2 | C22H20F3N5O3S = 491.49 | 5mg | QQ客服：215959384 |
| MLN8054; MLN8054 | CFN60224 | 869363-13-3 | C25H15ClF2N4O2 = 476.86 | 5mg | QQ客服：2056216494 |
| TW-37; TW-37 | CFN60225 | 877877-35-5 | C33H35NO6S = 573.7 | 5mg | QQ客服：2056216494 |
| 维莫德吉; Vismodegib (GDC-0449) | CFN60226 | 879085-55-9 | C19H14Cl2N2O3S = 421.3 | 5mg | QQ客服：3257982914 |
| Ganetespib (STA-9090); Ganetespib (STA-9090) | CFN60227 | 888216-25-9 | C20H20N4O3 = 364.4 | 5mg | QQ客服：215959384 |
| Nutlin-3; Nutlin-3 | CFN60228 | 890090-75-2 | C30H30Cl2N4O4 = 581.5 | 5mg | QQ客服：1457312923 |
| MK-8776 (SCH 900776); MK-8776 (SCH 900776) | CFN60229 | 891494-63-6 | C15H18BrN7 = 376.25 | 5mg | QQ客服：1457312923 |
| GDC-0879; GDC-0879 | CFN60230 | 905281-76-7 | C19H18N4O2 = 334.37 | 5mg | QQ客服：1457312923 |
| Rabusertib (LY2603618); Rabusertib (LY2603618) | CFN60231 | 911222-45-2 | C18H22BrN5O3 = 436.3 | 5mg | QQ客服：3257982914 |
| KU-60019; KU-60019 | CFN60232 | 925701-49-1 | C30H33N3O5S = 547.67 | 5mg | QQ客服：3257982914 |
Cell. 2018 Jan 11;172(1-2):249-261.e12. doi: 10.1016/j.cell.2017.12.019.IF=36.216(2019)
Cell Metab. 2020 Mar 3;31(3):534-548.e5. doi: 10.1016/j.cmet.2020.01.002.IF=22.415(2019)
Mol Cell. 2017 Nov 16;68(4):673-685.e6. doi: 10.1016/j.molcel.2017.10.022.IF=14.548(2019)
ACS Nano. 2018 Apr 24;12(4): 3385-3396. doi: 10.1021/acsnano.7b08969.IF=13.903(2019)
Nature Plants. 2016 Dec 22;3: 16206. doi: 10.1038/nplants.2016.205.IF=13.297(2019)
Sci Adv. 2018 Oct 24;4(10): eaat6994. doi: 10.1126/sciadv.aat6994.IF=12.804(2019)